# DISPATCHES

# Imipenem Resistance in *Clostridium difficile* Ribotype 017, Portugal

## Joana Isidro, Andrea Santos, Alexandra Nunes, Vítor Borges, Catarina Silva, Luís Vieira, Aristides L. Mendes, Mónica Serrano, Adriano O. Henriques, João Paulo Gomes, Mónica Oleastro

We describe imipenem-resistant and imipenem-susceptible clinical isolates of *Clostridium difficile* ribotype 017 in Portugal. All ribotype 017 isolates carried an extra penicillin-binding protein gene, *pbp5*, and the imipenem-resistant isolates had additional substitutions near the transpeptidase active sites of *pbp1* and *pbp3*. These clones could disseminate and contribute to imipenem resistance.

*Nostridium difficile*, a toxin-producing, spore-forming ∠ bacillus, is a main cause of nosocomial antimicrobial drug-associated diarrhea in industrialized countries (1). C. difficile infection (CDI) usually develops in previously hospitalized persons with a recent history of antimicrobial drug use and causes illness with symptoms ranging from mild diarrhea to potentially lethal pseudomembranous colitis (2). Antimicrobial drugs disrupt the protective gut microbiota, enabling ingested C. difficile spores to germinate in the colon and providing a selective advantage to nonsusceptible strains (3). CDI is mainly mediated by the TcdA and TcdB toxins, though some strains additionally produce a binary toxin. Multiple antimicrobial drugs can promote CDI, and cephalosporins and fluoroquinolones have been associated with a higher risk for CDI (3). Multidrug resistance is frequently found in epidemic C. difficile strains; determinants of resistance are often found in horizontally transferable mobile genetic elements (4). In past decades, CDI prominence has increased because of a sudden rise in outbreaks and an increase in disease severity and death (5). This shift was mainly associated with the dissemination of fluoroquinolone-resistant PCR ribotype (RT) 027, which has been responsible for hospital outbreaks worldwide. Strains of other ribotypes, including RT078 and RT017, which have enhanced

Author affiliations: National Institute of Health, Lisbon, Portugal (J. Isidro, A. Santos, A. Nunes, V. Borges, C. Silva, L. Vieira, J.P. Gomes, M. Oleastro); Instituto de Tecnologia Química e Biológica António Xavier, Oeiras, Portugal (A.L. Mendes, M. Serrano, A.O. Henriques)

DOI: https://doi.org/10.3201/eid2404.170095

virulence, have emerged (6). In particular, RT017, the most common toxin A-negative, toxin B-positive ribotype, is widespread in Asia and is common in Europe (7– 9). In a pan-European study of  $\approx$ 900 *C. difficile* strains, the overall rate of resistance to imipenem, an antimicrobial drug of the carbapenem class, currently widely used as a last-line drug to treat infections by gram-negative bacteria, was found to be 7.41%, and the geometric mean (GM) MIC of imipenem for RT017 strains was 5.91 mg/L (8). In another study, isolates collected in a South Korea hospital during 2000–2009 were analyzed, and a resistance rate to imipenem of 8% (12% among RT017 isolates) was found (*10*).

#### The Study

We characterized 191 *C. difficile* isolates collected during September 2012–September 2015 from 15 hospitals in Portugal (online Technical Appendix, https://wwwnc.cdc. gov/EID/article/24/4/17-0095-Techapp1.pdf). We found 24 (12.6%) were resistant to imipenem. Of these 24 isolates, 22 were RT017, 1 was RT014, and 1 was RT477. The MIC for imipenem for RT017, the imipenem-resistant isolates, was >32 mg/L (Table 1); the MIC for the 2 non-RT017 isolates was 16 mg/L. The 22 imipenem-resistant RT017 isolates were found at hospital A throughout the study period, suggesting the existence of a persistent clone, a finding supported by whole-genome sequencing data (online Technical Appendix). Among the 25 RT017 isolates, 3 were imipenem-susceptible and from hospital B (MIC range 1.5–3 mg/L) (Table 1).

RT017 C. difficile strains are frequently resistant to clindamycin, erythromycin, moxifloxacin, tetracycline, or rifampin (individually or in combination) (8,10). In this study, the 22 RT017 imipenem-resistant isolates were also found to be resistant to all of these antimicrobial drugs and showed higher meropenem and ertapenem MICs than those of the RT017 imipenem-susceptible isolates (Table 1; online Technical Appendix; online Technical Appendix Figure). Multidrug resistance to noncarbapenem antimicrobial drugs correlated with the presence of several genetic determinants, many located in mobile genetic elements (Figure 1; online Technical Appendix), in line with the idea that multidrug-resistant strains have a selective advantage (4) and that horizontal gene transfer plays a major role in the evolution of this pathogen (11).

#### DISPATCHES

			<u> </u>	<u> </u>								
		Antimicrobial drug, MIC breakpoints, mg/L										
	Resistance	IMP‡	ETP‡	MRP‡	MXF†§	MTZ†§	VAN†§	CLI‡	CHL‡	RIF†	TGC†	TET‡
Hospital	breakpoint†	<u>&gt;</u> 16	<u>&gt;</u> 16	<u>&gt;</u> 16	>4	>2	>2	<u>&gt;8</u>	<u>&gt;</u> 32	>0.004	>0.25	<u>&gt;</u> 16
A, 22	MIC range	>32	3–16	1.5–4	>32	<0.016–1	0.38–2	>256	2–6	>32	<0.016-0.094	16–32
isolates	GM MIC	32	7.56	2.31	32	0.12	0.73	256	3.29	32	0.025	18.08
	MIC <sub>90</sub>	32	12	3	>32	0.38	2	256	4	32	0.032	32
	MIC <sub>50</sub>	32	6	2	>32	0.19	0.75	256	3	32	0.023	16
	% Resistant	100	4.5	0	100	0	0	100	0	100	0	100
В, З	MIC range	1.5–3	1.5–2	0.5–1.5	1.5	<0.016-0.25	0.38–0.75	>256	3–4	>32	<0.016-0.023	16
isolates	GM MIC	2.08	1.82	0.83	1.5	0.072	0.60	256	3.30	32	0.020	16
	MIC <sub>90</sub>	3	2	1.5	1.5	0.25	0.75	256	4	32	0.023	16
	MIC <sub>50</sub>	2	2	0.75	1.5	0.094	0.75	256	3	32	0.023	16
	% Resistant	0	0	0	0	0	0	100	0	100	0	100
p value		< 0.0001	< 0.0001	<0.0001	< 0.0001	0.45	0.56	ND	0.98	ND	0.41	0.51

**Table 1.** Susceptibility of *Clostridium difficile* RT017 imipenem-resistant isolates from hospital A and imipenem-susceptible isolates from hospital B to 11 antimicrobial drugs, Portugal\*

\*CHL, chloramphenicol; CLI, clindamycin; ETP, ertapenem; GM, geometric mean; IMP, imipenem; MIC<sub>50</sub>, minimal inhibitory concentration for 50% of strains; MIC<sub>90</sub>, minimal inhibitory concentration for 90% of strains; MRP, meropenem; MTZ, metronidazole; MXF, moxifloxacin; ND, not done; RIF, rifampin; TGC, tigecycline; VAN, vancomycin.

†European Committee on Antimicrobial Susceptibility Testing breakpoint.

‡Clinical and Laboratory Standards Institute breakpoint.

§Previously determined (9).

Through whole-genome sequencing, we found 13 single-nucleotide polymorphisms (SNPs) that differentiated the imipenem-resistant and imipenem-susceptible RT017 isolates (Table 2; Figure 1; online Technical Appendix). We found 2 SNPs in the genes coding for 2 high molecular weight (HMW) penicillin-binding proteins (PBPs) (Figure 1). HMW PBPs, which are bifunctional enzymes containing transglycosylase and transpeptidase domains, are categorized into class A, and PBPs lacking the transglycosylase domain are categorized into class B. The transpeptidase domain harbors 3 functional motifs (SXXK, SXN, and KTG[T/S]) that comprise the active site. Carbapenems block cell wall synthesis by inhibiting transpeptidase activity (12). One of the mutations found in the imipenem-resistant isolates affected the gene coding for PBP1, the single class A bifunctional peptidoglycan synthase of C. difficile; the mutation resulted in the amino acid substitution Ala555Thr close to the SSN functional motif (Figure 2). The second mutation was found in the gene encoding for the PBP3 class B transpeptidase and caused the amino acid replacement Tyr721Ser between the SXN and KTGT motifs (Figure 2). Neither of these changes was found in the 3 imipenem-susceptible RT017 isolates (Figure 1). Moreover, the 2 non-RT017 imipenem-resistant isolates, with a MIC for imipenem lower than that of the RT017 isolates, revealed either the Ala555Thr change or a different substitution (Leu543His), both in PBP1, also close to the functional motif SXN (Table 2). Modified PBPs with reduced affinity for the antimicrobial drug have been associated with resistance to  $\beta$ -lactams and specifically to imipenem in several microorganisms (12). We found no differences between the imipenem-resistant and imipenem-susceptible RT017 isolates in genes encoding other peptidoglycan synthases (Figure 1). It is possible that the substitutions in PBP1 and PBP3 in RT017 confer high-level resistance to

imipenem and reduced susceptibility to other carbapenems, and at least in the RT014 and RT477 isolates studied, the single Ala555Thr substitution (or other substitutions in the vicinity of the SXN motif) is sufficient for an intermediate level of resistance.

However, all RT017 isolates studied herein, as well as the previously annotated strains M68 (GenBank accession no. NC 017175) and BJ08 (accession no. CP003939), have a fifth HMW class B PBP, PBP5, encoded in a mobile element (online Technical Appendix). Whether PBP5 contributes to imipenem resistance remains to be determined. Moreover, in imipenem-resistant isolates, the key sporulation-specific gene sigK, which is contiguous to *pbp2*, is interrupted by the 17-kb *skin*<sup>cd</sup> element (13), and the pbp5 region is contiguous to a transposon-like element carrying the ermB gene (shown as PUBMLST allele https://pubmlst.org/bigsdb?db=pubmlst cdifficile se 8; qdef&page=alleleInfo&locus=ermB&allele id=8). It is unknown whether these genetic differences contribute to imipenem resistance.

#### Conclusions

Imipenem resistance in *C. difficile* RT017 probably involves the acquisition of mutations in both *pbp1* and *pbp3* that lead to amino acid substitutions close to the functional motifs of their transpeptidase domains. These substitutions might decrease the affinity of PBP1 and PBP3 for imipenem, enabling peptidoglycan synthesis in the presence of the antimicrobial drug. Considering that the presence of an additional PBP (PBP5) is a characteristic of RT017 strains, we suggest that PBP5 facilitates the expression of imipenem resistance through acquisition of mutations in *pbp1* and *pbp3*. In strains of other ribotypes lacking PBP5, such as the RT014 and RT477 isolates herein described, mutations in *pbp1* might only lead to



**Figure 1.** Phylogeny of *Clostridium difficile* RT017 isolates from hospitals A and B and genetic determinants of antimicrobial drug resistance, Portugal. A) Core genome single-nucleotide polymorphism–based neighbor-joining phylogeny of 25 RT017 *C. difficile* clinical isolates reconstructed by using 47 variant sites (outside MGEs) identified when mapping to either the corresponding genomic sequence of close relative *C. difficile* strain M68 (GenBank accession no. NC\_017175) or a draft genome sequence of a representative clinical isolate. B) For each isolate, the profile of antimicrobial drug susceptibility is indicated together with respective potential genetic determinants of antimicrobial drug resistance. Only antimicrobial drugs for which a resistant phenotype was observed are displayed. Gene locus tags are relative to the *C. difficile* M68 genome annotation. Both nucleotide and amino acid replacements refer to mutations in the resistant isolates when comparing with susceptible isolates. No mutations means that no mutations are present differentiating resistant isolates of hospital A from susceptible isolates of hospital B, although mutations are present relative to M68. Both the *pbp5*-carrying region and the *ermB* gene (present in all isolates) were found to be inserted in distinct genomic contexts (online Technical Appendix, https://wwwnc.cdc.gov/EID/article/24/4/17-0095-Techapp1.pdf). MSLB, macrolide/ lincosamide/streptogramin B; MGE, mobile genetic element.

intermediate levels of resistance. We further suggest that the spreading of *pbp5* might contribute to the dissemination of high-level imipenem resistance.

Portugal has a high rate of healthcare-associated infections and is a major consumer of carbapenems (1). Although carbapenem consumption has not been directly linked to *C. difficile* resistance, we speculate that the emergence of resistance and reduced susceptibility to these antimicrobial drugs might recapitulate the scenario observed with fluoroquinolone-resistant RT027 in the United States, where fluoroquinolones were the most prescribed antimicrobial drug (14). Our findings further reinforce the need for the responsible use of antimicrobial

drugs; the emergence of carbapenem resistance in multidrug-resistant *C. difficile* clones might result in the dissemination of resistant strains.

#### Acknowledgments

We thank the participating hospitals for providing samples for the laboratory surveillance of CDI.

This work was supported by the National Institute of Health Dr. Ricardo Jorge (grant no. 2016DDI1284). We also acknowledge grant Pest-C/EQB/LA0006/2011 from Fundação para a Ciência e a Tecnologia (FCT; http://www.fct.pt) and program Investigador FCT (IF/00268/2013/CP1173/CT0006 to M.S.). A.L.M. was supported by a PhD fellowship (PD/BD/105738/2014) from the FCT.

Gene in M68	Genome	Nucleotide	Nucleotide		
genome*	position*	in M68	change†	Amino acid change†	Gene product
RS02665	512416	С	C578T	Ala193Val‡	Multidrug ATP-binding cassette transporter permease,
					associated with antimicrobial drug resistance
RS04280/ <i>pbp1</i>	905394	G	G1663A	Ala555Thr‡	Penicillin-binding transpeptidase
RS04935	1048151	С	T1010C	lle337Thr‡	3-Isopropylmalate dehydratase large subunit
RS05670/pbp3	1221182	G	A2162C	Tyr721Ser‡	Penicillin-binding protein
RS07765	1666351	G	G214T	Gly72§	Hypothetical protein
RS07795/hisB	1671129	Т	T209C	lle70Thr <sup>+</sup>	Imidazoleglycerol-phosphate dehydratase
RS07810	1673280	Т	C474T	Ala158Ala	Imidazoleglycerol-phosphate synthase cyclase subunit
RS08415	1792079	G	A241G	Lys81Glu‡	Hypothetical protein (domain of MerR-like
					transcriptional regulators)
RS08810	1882950	С	C420T	Asp140Asp	Flavodoxin
RS14235	3083548	G	G421T	Gly141§	Haloacid dehalogenase
RS18530	4054525	С	C220T	GIn74§	S-adenosyl methionine-dependent methyltransferase
RS19130/gyrA	4174650	С	C245T	Thr82lle <sup>±</sup>	DNA gyrase subunit A
RS19545	4255124	С	C400T	His134Tyr‡	Phage portal, SPP1 Gp6-like family protein

Table 2. Mutations differentiating Clostridium difficile RT017 imipenem-resistant isolates found at hospital A from imipenemsusceptible isolates found at hospital B, Portugal

\*Relative to the annotation of the C. difficile M68 genome (GenBank accession no. NC 017175).

†Changes observed between imipenem-resistant and imipenem-susceptible isolates.

‡Nonsynonymous mutations.

SMutations leading to putative protein truncation.

SSIK <sub>490</sub> SSN <sub>548</sub> KTGT <sub>692</sub> C. difficile PBP1 530 TT A G H G S M S L R K A L A K S S N T I A V K T Å E M - L G D S Y 563 S. aureus PBP2 438 D T K S H G T V S I Y D Å L R Q S F N I P A L K Å WQ S - V K Q N A 470 S. pneumoniae PBP2 432 Q A Y G S F P I T A V Q A L E Y S N T Y M V Q T A L G L MG Q T Y 465 E faecaclum PBP5 442 R V S D V S Q V D L K T A LI Y S D N Y M V Q T A L G L MG Q T Y 465 E faecaclum PBP5 446 R V S D V S Q V D L K T A LI Y S D N Y M A Q E T L K MG E 496 A555T T446A M485A A450D B V721S C. difficile PBP3 712 A Y T P A Q I S R Y V A A I A N G G N L V E L S V V D R A V S B D Y S V K I N D Q K K V E K I P F K N P 764 S aureus PBP2 502 E F S P T Q L A S F A A I A N G G N L V E L S V V D R A V S B D Y S V K I N D Q K K V E K I P F K N P E Y D H T S H 545 E. coll PBP2 459 T A T P I Q M S K A L M I L I N D G I V K V P H L L M S T A E D E Y D H T S H 545 E. coll PBP2 450 T A T P I Q A T M S V F Q N G T L V Y P K L V D K E T K E Y D H T S H 545 E. coll PBP4 546 L I S P I Q Q A T M Y S V F Q N N G T L V Y P K L V D K E T K E Y D H T S H 545 E. coll PBP3 765 D N L K E L T K G M K L - V A R Q G T A K S A F A D F P I D V A A K T G T A E K S G K I 807 S aureus PBP2 546 K A M S D Y T A Y M L A E M L K G T F K P Y G S A Y G N V I A A K T G T A E K S G K I 807 S aureus PBP2 546 K A M S D Y T A Y M L A E M L K G T F K P Y G S A Y G N V I A A K T G T A E K S G K I 807 S aureus PBP2 546 K A M S D Y T A Y M L A E M L K G T F K P Y G S A Y G N V I A A K T G T A E K S G K I 807 S aureus PBP2 546 K A M S D Y T A Y M L A E M L K G T F K P Y G S A Y G N V I A A K T G T A E K S G K I 807 S aureus PBP2 546 K A M S D Y T A Y M L A E M L K G T F K P Y G S A Y G N V I A A K T G T A E K S G K I 807 S aureus PBP2 546 K A M S D Y T A Y M L A E M L K G T F K P Y G S A Y G N V I A A K T G T A E K S G T A Q Y F Q I A K T G T A E K S G A Q Y F Q I A K T G T A E K S G A Q Y F Q I A K T G T A E K S G A Q Y F Q I A K T G T A	Α	N- <u>TM</u> [	TGase T	Pase –C	PBP1			
SSIK <sub>490</sub> SSN <sub>548</sub> KTGT <sub>692</sub> C. difficile PBP1 530 TT A G H G S M S L R K A L A K S S N T I A V K T A E M · L G D S Y 563 S. aureus PBP2 438 D T K S H G T V S I Y D A L R Q S F N I P A L K A WQS · V K Q N A 470 S. pneumoniae PBP2 432 Q A Y Q S F P I T A V Q A L E Y S N T Y M V Q T A L G L M Q Q T Y 465 E. faecacium PBP5 432 Q A Y Q S F P I T A V Q A L E Y S N T Y M V Q T A L G L M Q Q T Y 465 E. faecacium PBP5 464 R V S D V S Q V D L K T A L I Y S D N I Y M A Q E T L K M G E · · · 496 A555T T446A M485A A450D B V721S C. difficile PBP3 712 A Y T P A Q I S R Y V A A I A N G G N L V E L S V V D R A V S S D Y S V K I N D Q K K V E K I P F K N P · · 764 S aureus PBP2 502 E F S P T Q L A S A F A A I A N G G T Y N A H S I Q K V Y R D G E T I · · · · · · E Y D H T S H 545 E. coll PBP2 459 T A T P I Q M S K A L M I L I N D G I V V P H L L M S T A E D · · · · · G K Q V P W Q P H E 501 E. faecalis PBP4 546 L I S P I Q Q A T M Y S V F Q N N G T L V Y P K V L D K E T K · · · · · K K D N V I S A · · · S 855 C. difficile PBP3 765 · · · · D N L K E L T K G M K L · · V A R Q S T A · · K S A F A A F A D F P I D V A A K T G T A E K S G K I 807 S. aureus PBP2 546 K A M S D Y T A Y M L A E M L K G · · · T F K P Y G S A Y G H G V · · · A G V M G A K T G T A E K S G K I 807 S. aureus PBP3 765 · · · · · · D N L K E L T K G M K L · · V A R Q S T A · · K S A F A D F P I D V A A K T G T A E K S G K I 807 S. aureus PBP4 546 L S P I Q D I H S G Y W L A K D G M Y G V N R P N G T A · · · K Y F A S Q Y M G A Y G K G T A · · · K S A F A D F P I D V A A K T G T A E K S G K I 807 S. aureus PBP4 546 L S P I D V A A K T G T A E K S G K I 807 S. aureus PBP4 546 K A M S D T T A Y M L A E M L K G · · · · T F K P Y G S A Y G H G V · · · A G V M M G K T G T G Y G K S G A Y G K G C A Y G H G V · · · A G V M M G K T G T G Y G K S G A Y G H G V · · · Y M Y A A E H L K G G A Y G H Y · · P N F S L A A K T G T A E I K D K Q 6 29 V M C Y M C Y M Y A Y M L A E M L K G C · · · · Y M Y M Y P N F S L A A K T G T A E I K D K Q 29 M C Y M C Y M								
A555T C. difficile PBP1 530 TT A G H G S M SL R K A L A K S S N T I A V K T A E M - L G D S Y 563 S. aureus PBP2 438 D T K S H G T V S I Y D A L R Q S F N I P A L K A WQS - V K Q N A 470 S. pneumoniae PBP2b 432 Q A Y G S F P I T A V Q A L E Y S S N T Y M VQ T A L G L MG Q T Y 465 E faecacium PBP5 464 R V S D V S Q V D L K T A L I Y S D N I Y M A Q E T L K MGE 496 A555T T446A M485A A450D B NTM TPase C PBP3 Y721S C. difficile PBP3 712 A Y T P A Q I S R Y V A I A N G G N L V E L S V V D R A V S S D Y S S V K I N D Q K K V E K I P F K N P 764 S. aureus PBP2 502 E F S T Q L A S A F A A I A N G G T I N A H S I Q K V V R D G E T I E Y D H T S H 545 E. faecalis PBP4 546 L I S P I Q Q A T M Y S V F Q N N G T L V Y P K L V D K E T K		SSIK	SSN <sub>5</sub> ko K	TGT <sub>692</sub>				
A5551 S. aureus PBP2 438 D T K S H G T V S I Y D A L R Q S F N I P A L K A WQ S - V K Q N A 470 S. pneumoniae PBP2b 432 Q A Y G S F P I T A V Q A L E Y S S N T Y M V Q T A L G L M G Q T Y 465 E. faecacium PBP5 464 R V S D V S Q V D L K T A L I Y S D N I Y M A Q E T L K M G E 496 A555T T446A M485A A450D				002				
B. aureus PBP2 438 DT X S H G T X S H G T X Q A L R Q S F N I P A L K AWQS - V K Q N A 470 S. preumoniae PBP2b 438 DT X S H G T X Q A L R Q S F N I P A L K AWQS - V K Q N A 470 A555T T446A M485A A450D B. TM TPase C PBP3 Y721S C. difficile PBP3 712 A Y T P A Q I S R Y V A A I A N G G N L V E L S V V D R A V S S D Y S S V K I N D Q K K V E K I P F K N P - 764 S. aureus PBP2 502 E F S P T Q L A S A F A A I A N G G N L V E L S V V D R A V S S D Y S S V K I N D Q K K V E K I P F K N P - 764 S. aureus PBP2 502 E F S P T Q L A S A F A A I A N G G N L V E L S V V D R A V S S D Y S S V K I N D Q K K V E K I P F K N P - 764 S. aureus PBP2 502 E F S P T Q L A S A F A A I A N G G T V N A H S I Q K V V T R D G E T I E Y D H T S H 545 E. coli PBP2 459 T A T P I Q M S K A L M I L I N D G I V K V P H L L M S T A E D G K Q V P W Q P H E 501 E. faecalis PBP4 546 L I S P I Q Q A T M Y S V F Q N G T L V Y P K L V L D K E T K K K D N V I S A 585 S. aureus PBP2 502 F T D Q A T M Y S V F Q N N G T L V Y P K L V L D K E T K K K D N V A 585 C. difficile PBP3 765 D N L K E L T K G M K L V A R Q G T A K S A F A D F P I D V A A K T G T A E K S G K I 807 S. aureus PBP2 502 P V G D I H S G Y W L A K D G M Y G V N R P N G T A H K Y F A S A P Y K I A A K S G T A Q V F G K 544 E. coli PBP2 502 P P V G D I H S G Y W L A K D G M G V A N P N G T A H K Y F A S A P Y K I A A K S G T A Q V F G K 554 E. coli PBP2 502 P P V G D I H S G Y W E L A K D G M Y G V A N P N G T A H K Y F A S A P Y K I A A K S G T A Q V F G K 554 E. faecalis PBP4 566 N A A N T I A T D L L G S V E D P S G T W N Y N - P N F S L A A K T G T A E I K D K Q 629 V M Y A Y D Y A A K T G T A E I K D K Q 629 V M Y Y M Y - P N F S L A A K T G T A E I K D K Q 629 V M Y Y M Y - P N F S L A A K T G T A E I K D K Q 629	C difficilo	DDD1			KSSNTLAV		( 563	
B S. preumoniae PBP2b 432 Q A Y G S F P I T A V Q A L E Y S S N T Y M V Q T A L G L M G Q T Y 465 E. faecacium PBP5 464 R V S D V S Q V D L K T A L I Y S D N I Y M A Q E T L K M G E 496 A555T T446A M485A A450D		PBP1	438 D T K S H G T		OSENI PAL	KAWOS-VKONA	470	
E. faecacium PBP5 464 R V S D V S Q V D L K T A L I Y S D N I Y M A Q E T L K M G E 496 A555T T446A M485A A450D	S pneumon	iae PBP2h	432 0 A Y G S F P		YSSNTYMV	OTAL GL MGOT	465	
A555T T446A M485A A450D <b>B I I I I I I I I I I</b>	E. faecaciur	n PBP5	464 R V S D V S Q	VDLKTALI	YSDNIYMA	QETLKMGE	496	
B VT21S SSIK <sub>495</sub> SSN <sub>552</sub> KTGT <sub>800</sub> V721S C. difficile PBP3 712 A YT P A QI S RY VA AI A N G G N L V E L S V V D R A V S S D Y S V K I N D Q K K V E K I P F K N P - 764 S. aureus PBP2 502 E F S P T Q L A S A F A AI A N G G T Y N N A H S I Q K V V T R D G E T I E Y D H T S H 545 E. coli PBP2 459 T A T P I Q M S K A L MI L I N D G I V K V P H L M S T A E D				A555T	T460 M4950			
B V721S C. difficile SSIK <sub>495</sub> SSN <sub>552</sub> KTGT <sub>800</sub> V721S C. difficile BP2 502 EFSPTQLASAFAAIANGGNLVELSVVDRAVSSDYSSVKINDQKKVEKIPFKNP 764 S. aureus PB2 502 EFSPTQLASAFAAIANGGTYNNAHSIQKVVTRDGETIEYDHTSH 545 E. coli PB2 459 TATPIQMSKALMILINDGIVKVPHLLMSTAED				A0001	1440A 101400A	A400D		
B V721S C. difficile PBP3 712 A YT PAQI S R Y721S C. difficile PBP3 712 A YT PAQI S R Y VAAI ANGGNLVELSVVDRAVSSDYSSVKI NDQKKVEKI PFKNP764 S. aureus PBP2 502 EFSPTQLASAFAAI ANGGTYNNAHSI QKVVTRDGETIEYDHTSH 545 E. coli PBP2 459 TATPI QMSKALMI LI NDGI VKVPHLLMSTAED	_							
Y721S    SSIK <sub>495</sub> SSN <sub>552</sub> KTGT <sub>800</sub> Y721S    C. difficile  PBP3    712  AYTPAQISR    Y721S    Saureus  PBP2    502  EFSPTQLASAFAAIANGGNLVELSVVDRAVSSDYSSVKINDQKKVEKIPFKNP    764    S. aureus  PBP2    502  EFSPTQLASAFAAIANGGTYNNAHSIQKVVTRDGETI	R	N-TM-	TPase - (	2	PBP3			
SSIK <sub>495</sub> SSN <sub>552</sub> KTGT <sub>800</sub> Y721S C. difficile PBP3 712 A Y T P A QI S R Y V A AI A N G G N L V E L S V V D R A V S S D Y S V K I N D Q K K V E K I P F K N P - 764 S. aureus PBP2 502 E F S P T Q L A S A F A AI A N G G T Y N N A H S I Q K V T R D G E T I E Y D H T S H 545 E. coli PBP2 459 T A T P I Q M S K A L M I L I N D G I V K V P H L M S T A E D G K Q V P W V Q P H E 501 E. faecalis PBP4 546 L I S P I Q Q A T M Y S V F Q N N G T L V Y P K L V L D K E T K K K D N V I S A 585 Score Status PBP2 566 D N L K E L T K G M K L - V A R Q G T A K S A F A D F P I D V A A K T G T A E K S G K I 807 S. aureus PBP2 546 K A M S D Y T A Y M L A E M L K G T F K P Y G S A Y G H G V A G V N M G A K T G T A E K S G K I 807 E. coli PBP2 502 P P V G D I H S G Y W E L A K D G M Y G V A N R P N G T A H K Y F A S A P Y K I A A K S G T A Q V F G L K 554 E. faecalis PBP4 586 N A A N T I A T D L L G S V E D P S G T V - Y M M Y N - P N F S L A A K T G T A E I K D K Q 629			Y721	S				
SSIK <sub>495</sub> SSN <sub>552</sub> KTGT <sub>800</sub> Y721S C. difficile PBP3 712 A Y T P A QI S R Y V A AI A N G G N L V E L S V V D R A V S S D Y S V K I N D Q K K V E K I P F K N P - 764 S. aureus PBP2 502 E F S P T Q L A S A F A AI A N G G T Y N N A H S I Q K V V T R D G E T I E Y D H T S H 545 E. coli PBP2 459 T A T P I Q M S K A L M I L I N D G I V K V P H L L M S T A E D G K Q V P W V Q P H E 501 E. faecalis PBP4 546 L I S P I Q Q A T M Y S V F Q N N G T L V Y P K L V L D K E T K K K D N V I S A 585 C. difficile PBP3 765 D N L K E L T K G M K L V A R Q G T A K S A F A D F P I D V A A K T G T A E K S G K I 807 S. aureus PBP2 546 K A M S D Y T A Y M L A E M L K G T F K P Y G S A Y G H G V A G V N M G A K T G T A E K S G K I 807 E. coli PBP2 502 P P V G D I H S G Y W E L A K D G M Y G V A N R P N G T A - H K Y F A S A P Y K I A A K S G T A Q V F G L K 554 E. faecalis PBP4 586 N A A N T I A T D L L G S V E D P S G T V - Y M M Y N - P N F S L A A K T G T A E I K D K Q 629		and the second s						
SSIK <sub>495</sub> SSN <sub>552</sub> KTGT <sub>800</sub> Y721S C. difficile PBP3 712 AYTPAQISRYVAAIANGGNLVELSVVDRAVSSDYSSVKINDQKKVEKIPFKNP764 S. aureus PBP2 502 EFSPTQLASAFAAIANGGTYNNAHSIQKVVTRDGETI								
Y721S C. difficile PBP3 712 A Y T P A QI S R Y V A AI A N G G N L V E L S V V D R A V S S D Y S V K I N D Q K K V E K I P F K N P - 764 S. aureus PBP2 502 E F S P T Q L A S A F A AI A N G G T Y N N A H S I Q K V V T R D G E T I E Y D H T S H 545 E. coli PBP2 459 T A T P I Q M S K A L M I L I N D G I V K V P H L L M S T A E D G K Q V P W V Q P H E 501 E. faecalis PBP4 546 L I S P I Q Q A T M Y S V F Q N N G T L V Y P K L V L D K E T K K K D N V I S A 585 C. difficile PBP3 765 D N L K E L T K G M K L V A R Q G T A K S A F A D F P I D V A A K T G T A E K S G K I 807 S. aureus PBP2 546 K A M S D Y T A Y M L A E M L K G T F K P Y G S A Y G H G V A G V N M G A K T G T G T Y G A - 591 E. coli PBP2 502 P P V G D I H S G Y W E L A K D G M Y G V A N R P N G T A H K Y F A S A P Y K I A A K S G T A Q V F G L K 554 E. faecalis PBP4 586 N A A N T I A T D L L G S V E D P S G T V - Y N M Y N - P N F S L A A K T G T A E I K D K Q 629		SSIK <sub>495</sub>	SSN 552	KTGT				
Y721S    C. difficile  PBP3  712  A Y T P A QI S R Y V A AI A N G G N L V E L S V V D R A V S S D Y S V K I N D Q K K V E K I P F K N P - 764    S. aureus  PBP2  502  E F S P T Q L A S A F A AI A N G G T Y N N A H S I Q K V V T R D G E T I E Y D H T S H 545    E. coli  PBP2  459  T A T P I Q M S K A L M I L I N D G I V K V P H L L M S T A E D G K Q V P W V Q P H E 501    E. coli  PBP4  546  L I S P I Q Q A T M Y S V F Q N N G T L V Y P K L V L D K E T K K K D N V I S A 585    C. difficile  PBP3  765  D N L K E L T K G M K L - V A R Q G T A K S A F A D F P I D V A A K T G T A E K S G K I 807    S. aureus  PBP2  546  K A M S D Y T A Y M L A E M L K G T F K P Y G S A Y G H G V A G V N M G A K T G T G T Y G A - 591    E. coli  PBP2  502  P V G D I H S G Y W E L A K D G M Y G V A N R P N G T A H K Y F A S A P Y K I A A K S G T A Q V F G L K 554    E. faecalis  PBP4  586  N A A N T I A T D L L G S V E D P S G T V - Y N M Y N - P N F S L A A K T G T A E I K D K Q 629		100	552	1 1 0 1 800				
C. difficile  PBP3  712  A Y T P A QI S R Y V A AI A N G G N L V E L S V V D R A V S S D Y S S V KI N D Q K K V E KI P F K N P - 764    S. aureus  PBP2  502  E F S P T Q L A S A F A AI A N G G T Y N N A H S I Q K V V T R D G E T I E Y D H T S H 545    E. coli  PBP2  459  T A T P I Q M S K A L M I L I N D G I V K V P H L L M S T A E D G K Q V P W V Q P H E 501    E. coli  PBP4  546  L I S P I Q Q A T M Y S V F Q N N G T L V Y P K L V L D K E T K K K D N V I S A 585    C. difficile  PBP3  765  D N L K E L T K G M K L - V A R Q G T A K S A F A D F P I D V A A K T G T A E K S G K I 807    S. aureus  PBP2  546  K A M S D Y T A Y M L A E M L K G T F K P Y G S A Y G H G V A G V N M G A K T G T G T Y G A - 591    E. coli  PBP2  502  P V G D I H S G Y W E L A K D G M Y G V A N R P N G T A H K Y F A S A P Y K I A A K S G T A Q V F G L K 554    E. faecalis  PBP4  586  N A A N T I A T D L L G S V E D P S G T V - Y N M Y N - P N F S L A A K T G T A E I K D K Q 629				Y721S				
S. aureus  PBP2  502  EFSPTQLASAFAAIANGGTYNNAHSIQKVVTRDGETIEYDHTSH545    E. coli  PBP2  459  TATPIQMSKALMILINDGIVKVPHLLMSTAEDGKQVPWVQPHE501    E. faecalis  PBP4  546  LISPIQQATMYSVFQNNGTLVYPKLVLDKETK	C. difficile	PBP3	712 AYTPAQI	SRYVAALA	NGGNLVEL	SVVDRAVSSDY	SSVKI NDQKKVEKI I	PFKNP 764
E. coli  PBP2  459  T A T P I Q M S K A L M I L I N D G I V K V P H L L M S T A E D G K Q V P W V Q P H E 501    E. faecalis  PBP4  546  L I S P I Q Q A T M Y S V F Q N N G T L V Y P K L V L D K E T K K K D N V I S A 585    C. difficile  PBP3  765  D N L K E L T K G M K L - V A R Q G T A K S A F A D F P I D V A A K T G T A E K S G K I 807    S. aureus  PBP2  546  K A M S D Y T A Y M L A E M L K G T F K P Y G S A Y G H G V A G V N M G A K T G T G T Y G A 591    E. coli  PBP2  502  P V G D I H S G Y W E L A K D G M Y G V A N R P N G T A H K Y F A S A P Y K I A A K S G T A Q V F G L K 554    E. faecalis  PBP4  586  N A A N T I A T D L L G S V E D P S G T V - Y N M Y N - P N F S L A A K T G T A E I K D K Q 629	S. aureus	PBP2	502 EFSPTQL	ASAFAAIA	ΝGGTΥΝΝΑ	HSI QKVVTRDO	) E T I I	EYDHTSH 545
E. faecalis  PBP4  546  LISPIQQATMYSVFQNNGTLVYPKLVLDKETKKKDNVISA585    S669A  A462V  T547A/I    C. difficile  PBP3  765	E. coli	PBP2	459 TATPIQM	SKALMILI	NDGI VKVP	HLLMSTAED	GKQVI	PWVQPHE 501
C. difficile  PBP3  765  765	E. faecalis	PBP4	546 LISPIQQ	ATMYSVFQ	NNGTLVYP	KLVLDKETK	KKDN	VISA 585
C. difficile  PBP3  765 DNLKELTKGMKL VARQGTA KSAFADFPIDVAAKTGTAEKSGKI 807    S. aureus  PBP2  546  KAMSDYTAYMLAEMLKG TFKPYGSAYGHGV AGVNMGAKTGTGTYGA 591    E. coli  PBP2  502  PPVGDIHSGYWELAKDGMYGVANRPNGTA - HKYFASAPYKIAAKSGTAQVFGLK 554    E. faecalis  PBP4  586 NAANTIATDLLGSVEDPSGTV - YNMYN - PNFSLAAKTGTAEIKDKQ 629	1					S569A	A462V T5	47A/I
S. aureus  PBP2  546  K A M S D Y T A Y M L A E M L K G T F K P Y G S A Y G H G V A G V N M G A K T G T G T Y G A 591    E. coli  PBP2  502  P P V G D I H S G Y W E L A K D G M Y G V A N R P N G T A H K Y F A S A P Y K I A A K S G T A Q V F G L K 554    E. faecalis  PBP4  586  N A A N T I A T D L L G S V E D P S G T V Y N M Y N - P N F S L A A K T G T A E I K D K Q 629	C. difficile	PBP3	765	- DNLKELT	KGMKLV	ARQGTA KSA	FAD <u>F</u> PI DVAAKTGT	AEKSGKI 807
E. coli PBP2 502 PPVGDIHSGYWELAKDGMYGVANRPNGTAHKYFASAPYKIAAKSGTAQVFGLK 554 E. faecalis PBP4 586NAANTIATDLLGSVEDPSGTVYNMYN-PNFSLAAKTGTAEIKDKQ 629	S. aureus	PBP2	546 KAMSDYT	AYMLAEML	KGTF	K	<mark>A</mark> G V N M G A K T G T (	GTYGA 591
E. faecalis PBP4 586 NAANTIATDLLGSVEDPSGTV - YNMYN - PNFSLAAKTGTAEIKDKQ 629	E. coli	PBP2	502 PPVGDIH	SGYWELAK	DGMYGVAN	R P N G <u>T</u> A -   - <del>H</del> K Y	FASAPYKI AAKSG <mark>T</mark> A	AQVFGLK 554
VCOELL	E. faecalis	PBP4	586	- NAANTIA	TDLLGSVE	D P S G T V <mark>Y</mark> N N	IYN-PNFSLAAKTGT	AEIKDKQ 629
						Y605H	I Q629D	
C. amicile PBP3 808 PIDNEYEYLKSHMSSYNV	C. difficile	PBP3	808 PTDNE		YEYLKSHM	S S Y N V		825
IS AUFEUS PBP2 592 - EIYSQYNLPDNAAKAYWINGFIPQYIMSVWMGFSKVKQYGENSFVGHS 639	S. aureus	PBP2	592 E I Y S Q	YNLPDNAA		I PQYIMS		SEVGHS 639
E. COM PEPZ 303 ANELYNAHKI AEKLKUMKA MIAFAFYNNPQVAVAMI LENGGAGPAVGIL 602		1 11 21 17 2					A / · ·	

M574I

Figure 2. Amino acid substitutions in 2 PBPs predicted to be associated with imipenem resistance in Clostridium difficile, Portugal. The domains and conserved motifs SXXK, SXN, and KTG[T/S] are shown for the following proteins: PBP1 (A), homolog of CDM68 RS04280 of RT017 strain M68 (GenBank accession no. NC 017175) or CD630 07810 in the laboratory strain 630; and PBP3 (B), homolog of CDM68 RS05670 or CD630 11480. The mutations found in these resistant isolates are marked by red lines. The alignments below the 2 proteins show the position (shaded in pink) and nature of the amino acid substitutions observed in the imipenemresistant RT017 isolates and select PBPs from microorganisms Staphylococcus aureus (GenBank accession no. AAA74375.1), Streptococcus pneumoniae (GenBank accession no. WP 001829432.1), Escherichia coli (GenBank accession no. AAB40835.1), Enterococcus faecalis (GenBank accession no. AAS77615.1), and Enterococcus faecacium (GenBank accession no. AIG13039.1). The conserved motifs in the vicinity of the substitutions are shaded in blue. PBP, penicillin-binding protein; TGase, transglycosylase; TM, transmembrane; TPase, transpeptidase.

## About the Author

Dr. Isidro is a fellow in the Reference Laboratory for Gastrointestinal Infections at the National Institute of Health Dr. Ricardo Jorge in Lisbon, Portugal. Her primary research interests include CDI, antibiotic resistance, molecular typing, and wholegenome sequencing.

### References

- European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals, 2011–2012. Stockholm: The Centre; 2013.
- Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. *Clostridium difficile* infection. Nat Rev Dis Primers. 2016;2:201620.
- Slimings C, Riley TV. Antibiotics and hospital-acquired *Clostridium difficile* infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69:881–91. http://dx.doi.org/10.1093/jac/dkt477
- Spigaglia P. Recent advances in the understanding of antibiotic resistance in *Clostridium difficile* infection. Ther Adv Infect Dis. 2016;3:23–42. http://dx.doi.org/10.1177/2049936115622891
- Gerding DN, Lessa FC. The epidemiology of *Clostridium* difficile infection inside and outside health care institutions. Infect Dis Clin North Am. 2015;29:37–50. http://dx.doi.org/ 10.1016/j.idc.2014.11.004
- Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, et al. The changing epidemiology of *Clostridium difficile* infections. Clin Microbiol Rev. 2010;23:529–49. http://dx.doi.org/10.1128/CMR.00082-09
- King AM, Mackin KE, Lyras D. Emergence of toxin A-negative, toxin B-positive *Clostridium difficile* strains: epidemiological and clinical considerations. Future Microbiol. 2015;10:1–4. http://dx.doi.org/10.2217/fmb.14.115
- Freeman J, Vernon J, Morris K, Nicholson S, Todhunter S, Longshaw C, et al.; Pan-European Longitudinal Surveillance of

Antibiotic Resistance among Prevalent Clostridium difficile Ribotypes' Study Group. Pan-European longitudinal surveillance of antibiotic resistance among prevalent *Clostridium difficile* ribotypes. Clin Microbiol Infect. 2015;21:248.e9–16. http://dx.doi.org/10.1016/j.cmi.2014.09.017

- Santos A, Isidro J, Silva C, Boaventura L, Diogo J, Faustino A, et al. Molecular and epidemiologic study of *Clostridium difficile* reveals unusual heterogeneity in clinical strains circulating in different regions in Portugal. Clin Microbiol Infect. 2016;22:695– 700. http://dx.doi.org/10.1016/j.cmi.2016.04.002
- Lee JH, Lee Y, Lee K, Riley TV, Kim H. The changes of PCR ribotype and antimicrobial resistance of *Clostridium difficile* in a tertiary care hospital over 10 years. J Med Microbiol. 2014;63:819– 23. http://dx.doi.org/10.1099/jmm.0.072082-0
- He M, Sebaihia M, Lawley TD, Stabler RA, Dawson LF, Martin MJ, et al. Evolutionary dynamics of *Clostridium difficile* over short and long time scales. Proc Natl Acad Sci U S A. 2010;107:7527–32. http://dx.doi.org/10.1073/pnas.0914322107
- Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and β-lactam resistance. FEMS Microbiol Rev. 2008;32:361–85. http://dx.doi.org/10.1111/j.1574-6976.2007.00095.x
- Serrano M, Kint N, Pereira FC, Saujet L, Boudry P, Dupuy B, et al. A recombination directionality factor controls the cell type-specific activation of σ<sup>K</sup> and the fidelity of spore development in *Clostridium difficile*. PLoS Genet. 2016;12:e1006312. http://dx.doi.org/10.1371/journal.pgen.1006312
- He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, et al. Emergence and global spread of epidemic healthcare– associated *Clostridium difficile*. Nat Genet. 2013;45:109–13. http://dx.doi.org/10.1038/ng.2478

Address for correspondence: Mónica Oleastro, National Institute of Health Dr. Ricardo Jorge, National Reference Laboratory for Gastrointestinal Infections, Department of Infectious Diseases, Av Padre Cruz, 1649-016 Lisbon, Portugal; email: monica.oleastro@insa.min-saude.pt

# **PubMed Central**



Find *Emerging Infectious Diseases* content in the digital archives of the National Library of Medicine

www.pubmedcentral.nih.gov